Table 2.
RC pharmacokinetic parameters after the oral administration of the coated capsules filled with the optimized formulations containing mannitol (OFM) or Aerosil (OFA), compared to the market product.
| Pharmacokinetics Parameters | Treatment (Mean ± SD) a | ||
|---|---|---|---|
| OFM | OFA | The Market Product | |
| Cmax (ng/mL) | 6.08 ± 0.52 | 10.84 ± 1.02 | 2.83 ± 0.94 |
| AUC0-24 (ng.h/mL) | 26.22 ± 1.87 | 71.71 ± 3.98 | 23.02 ± 1.36 |
| AUC0-∞ (ng.h/mL) | 29.92 ± 1.24 | 86.16 ± 5.21 | 27.38 ± 2.09 |
| Tmax (h) | 3.00 | 3.00 | 1.00 |
| Ke (l/h) | 0.06 ± 0.00 | 0.07 ± 0.00 | 0.07 ± 0.00 |
| t½e (h) | 10.92 ± 1.13 | 10.01 ± 1.89 | 9.63 ± 0.82 |
| MRT | 9.80 | 12.66 | 12.17 |
| % Relative Bioavailability | 109.28% | 314.68% | - |
a Median of Tmax and MRT are displayed instead of the mean values.